Novartis’s 4Q17 Earnings: Alcon Business

Alcon

Alcon, Novartis AG’s (NVS) Eye Care business, includes both surgical and vision care products in its portfolio. The segment’s ophthalmic pharmaceuticals products were transferred to its Innovative Medicines business in 2016.

Alcon reported revenues of ~$1.6 billion in 4Q17 for 8.0% growth in revenues compared to ~$1.4 billion in 4Q16.

Novartis’s 4Q17 Earnings: Alcon Business

The chart above compares revenues for Alcon since 1Q16. In 4Q17, its revenues reported 6.0% growth at constant exchange rates and a 2.0% positive impact of foreign exchange.

4Q17 performance

Alcon’s Surgical franchise reported 9.0% growth in revenues at constant exchange rates. Its Vision Care franchise reported 2.0% growth in revenues at constant exchange rates in 4Q17.

Geographically, the segment reported operational growth across all markets. Foreign exchange had a positive impact on all markets.

Its US sales increased ~3.0% to $639.0 million, while sales from its European markets increased by ~11.0% to $420.0 million in 4Q17. The Asia, Africa, and Australasia markets reported 15.0% growth in sales to ~$377.0 million. Its Canada and Latin America markets reported 10.0% growth in sales to ~$122.0 million in 4Q17.

Surgical franchise

Sales for the Surgical franchise reported 9.0% growth in operating revenues to $982.0 million in 4Q17 compared to revenues of $887.0 million in 4Q16.

This growth was driven by increased global sales of cataract consumable products, vitreoretinal products, refractive products, and intraocular lenses. This growth was partially offset by lower sales of cataract equipment.

Vision Care franchise

The Vision Care franchise reported 4.0% growth in operating revenues to $582.0 million in 4Q17 compared to revenues of $557.0 million in 4Q16. This growth was driven by the increased sales of contact lenses and contact lens care products in 4Q17.

The Vanguard FTSE Developed Markets ETF (VEA) holds 8.6% of its total investments in healthcare companies. VEA holds 0.9% in Novartis AG (NVS), 0.5% in Novo Nordisk (NVO), 0.4% in AstraZeneca (AZN), and 0.4% in GlaxoSmithKline (GSK).